Oxbow Advisors LLC Purchases 24,141 Shares of Zoetis Inc. (NYSE:ZTS)

Oxbow Advisors LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 768.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 27,284 shares of the company’s stock after acquiring an additional 24,141 shares during the quarter. Oxbow Advisors LLC’s holdings in Zoetis were worth $4,445,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. AMF Tjanstepension AB grew its stake in shares of Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after acquiring an additional 20,001 shares during the period. Howard Capital Management Group LLC boosted its stake in Zoetis by 0.8% in the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Zoetis by 8.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock worth $10,882,000 after purchasing an additional 4,107 shares during the period. Courier Capital LLC boosted its stake in Zoetis by 80.7% in the 3rd quarter. Courier Capital LLC now owns 2,740 shares of the company’s stock worth $535,000 after purchasing an additional 1,224 shares during the period. Finally, International Assets Investment Management LLC boosted its stake in Zoetis by 41,235.7% in the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after purchasing an additional 937,700 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $160.39 on Friday. The stock has a market cap of $71.82 billion, a price-to-earnings ratio of 29.32, a P/E/G ratio of 2.78 and a beta of 0.90. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The stock’s 50-day moving average is $166.51 and its 200 day moving average is $178.04.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.25%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Analyst Upgrades and Downgrades

Several brokerages have commented on ZTS. Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Piper Sandler cut their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Stifel Nicolaus cut their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $214.90.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.